Plus Therapeutics (PSTV) Net Margin (2011 - 2026)
Plus Therapeutics (PSTV) reported Net Margin of 675.68% for Q1 2026, down 29013.0% year-over-year from N/an in Q1 2025, and down 61.68% quarter-over-quarter from 417.92% in Q4 2025.
Plus Therapeutics (PSTV) Net Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 14 years of Net Margin data on file, last reported at 675.68% in Q1 2026.
- Net Margin for Q1 2026 came in at 675.68%, down 29013.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 358.8% (down 6255.0% YoY), and the FY2025 annual result was 301.75%, down 5104.0% from the prior year.
- Net Margin retreated to 675.68% in Q1 2026 per PSTV's latest filing, from 417.92% in the prior quarter.
- Over five years, Net Margin peaked at 73.16% in Q3 2023 and troughed at 7186.3% in Q3 2022.
- A 5-year average of 1061.92% and a median of 290.18% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2026: Net Margin jumped 711314 bps in 2023, then slumped 29013 bps in 2026.
- A 5-year view of Net Margin shows it stood at 4417.32% in 2022, then surged by 93 bps to 290.18% in 2023, then gained by 5 bps to 276.42% in 2024, then slumped by 51 bps to 417.92% in 2025, then tumbled by 62 bps to 675.68% in 2026.
- Business Quant data shows PSTV's Net Margin at 675.68% in Q1 2026, 417.92% in Q4 2025, and 316.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | -675.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -675.68% |
| Dec 31, 2025 | -417.92% |
| Sep 30, 2025 | -316.61% |
| Jun 30, 2025 | -108.71% |
| Mar 31, 2025 | -385.55% |
| Dec 31, 2024 | -276.42% |
| Sep 30, 2024 | -259.62% |
| Jun 30, 2024 | -285.93% |
| Mar 31, 2024 | -194.45% |
| Dec 31, 2023 | -290.18% |
| Sep 30, 2023 | -73.16% |
| Jun 30, 2023 | -79.94% |
| Mar 31, 2023 | -961.00% |
| Dec 31, 2022 | -4,417.32% |
| Sep 30, 2022 | -7,186.30% |
| Mar 31, 2019 | -97.58% |
| Dec 31, 2018 | -141.35% |
| Sep 30, 2018 | -452.56% |
| Jun 30, 2018 | -208.18% |
| Mar 31, 2018 | -651.30% |